Overlook Medical Center
- Type
- Teaching hospital
- Where
- Summit, NJ
- Medicare CCN
- 310051
- Received
- $450,411 in 57 records, 2020 ($13,126 general, $437,284 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 7 | $13,126 |
| 2020 | Research payment | 50 | $437,284 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Celgene Corporation | 2 | $228,151 | 2020 |
| BeiGene, Ltd. | 1 | $60,134 | 2020 |
| Penumbra, Inc. | 15 | $49,140 | 2020 |
| Janssen Research & Development, LLC | 6 | $38,963 | 2020 |
| Astellas Pharma Global Development | 2 | $26,000 | 2020 |
| GENZYME CORPORATION | 16 | $16,117 | 2020 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $13,527 | 2020 |
| Siemens Medical Solutions USA, Inc. | 2 | $8,214 | 2020 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $4,250 | 2020 |
| Amgen Inc. | 1 | $3,000 | 2020 |
| Merck Sharp & Dohme LLC | 1 | $2,000 | 2020 |
| Janssen Pharmaceuticals, Inc | 1 | $700 | 2020 |
| Becton, Dickinson and Company | 2 | $212 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 50 | $437,284 |
| Charitable Contribution | 2 | $8,214 |
| Space rental or facility fees (teaching hospital only) | 3 | $4,700 |
| Education | 2 | $212 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $339 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-17 | Penumbra, Inc. | $15,911 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-12-10 | Penumbra, Inc. | $2,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-12-10 | Penumbra, Inc. | $1,386 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-11-21 | Amgen Inc. | $3,000 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | Cardiovascular Multi-dimensional Observational Investigation of the Use of PCSK9i (cvMOBIUS) | 2020 |
| 2020-11-19 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-11-12 | Penumbra, Inc. | $865 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-11-09 | GENZYME CORPORATION | $1,300 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-11-09 | GENZYME CORPORATION | $1,072 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-11-09 | GENZYME CORPORATION | $455 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-10-29 | Takeda Pharmaceuticals U.S.A., Inc. | $10,327 | Research payment | Cash or cash equivalent | A FOLLOW-UP OF A PHASE 3 STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF DARVADSTROCEL IN THE TREATMENT OF COMPLE | 2020 | |
| 2020-10-29 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-10-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,200 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2020 | |
| 2020-10-08 | Penumbra, Inc. | $489 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-10-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2020 |
| 2020-10-07 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2020 |
| 2020-10-05 | GENZYME CORPORATION | $791 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-10-05 | GENZYME CORPORATION | $791 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-10-05 | GENZYME CORPORATION | $791 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-09-24 | Bayer Healthcare Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2020 |
| 2020-09-23 | Celgene Corporation | $1,000 | Research payment | Cash or cash equivalent | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | 2020 | |
| 2020-09-21 | Becton, Dickinson and Company | $106 | Education | In-kind items and services | 2020 | ||
| 2020-09-02 | GENZYME CORPORATION | $2,340 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-09-02 | GENZYME CORPORATION | $455 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-08-12 | Penumbra, Inc. | $489 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-07-31 | Becton, Dickinson and Company | $106 | Education | In-kind items and services | 2020 | ||
| 2020-07-08 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-07-01 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Phase III RB/RCHOP +/- copanlisib in iNHL | 2020 |
| 2020-06-29 | Siemens Medical Solutions USA, Inc. | $7,875 | Charitable Contribution | Cash or cash equivalent | Mobilett Mira Max Device, DI - X-Ray Products | 2020 | |
| 2020-06-01 | BeiGene, Ltd. | $60,134 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COV | 2020 |
| 2020-05-21 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety an | 2020 | |
| 2020-05-21 | Janssen Research & Development, LLC | $1,200 | Research payment | Cash or cash equivalent | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety an | 2020 | |
| 2020-05-20 | Penumbra, Inc. | $1,788 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-05-04 | GENZYME CORPORATION | $1,852 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-05-04 | GENZYME CORPORATION | $1,625 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-05-04 | GENZYME CORPORATION | $910 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-04-23 | Penumbra, Inc. | $1,000 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-04-16 | Astellas Pharma Global Development | $15,000 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | RANDOMIZED TRIAL OF GILTERITINIB VS MIDOSTAURIN IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML | 2020 |
| 2020-04-16 | Astellas Pharma Global Development | $11,000 | Research payment | Cash or cash equivalent | XOSPATA Drug, ONCOLOGY | RANDOMIZED TRIAL OF GILTERITINIB VS MIDOSTAURIN IN FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML | 2020 |
| 2020-04-06 | GENZYME CORPORATION | $1,000 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-04-06 | GENZYME CORPORATION | $500 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-04-06 | GENZYME CORPORATION | $250 | Research payment | Cash or cash equivalent | HECTOROL Drug, Genetic Disease | An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules) | 2020 |
| 2020-03-30 | Janssen Research & Development, LLC | $3,000 | Research payment | Cash or cash equivalent | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety an | 2020 | |
| 2020-03-26 | Penumbra, Inc. | $8,437 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-03-19 | Janssen Research & Development, LLC | $22,763 | Research payment | Cash or cash equivalent | A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety an | 2020 | |
| 2020-03-09 | GENZYME CORPORATION | $1,625 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-03-09 | GENZYME CORPORATION | $357 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-02-27 | Penumbra, Inc. | $6,513 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-02-10 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | NINLARO Drug, ONCOLOGY | 2020 | |
| 2020-02-06 | Penumbra, Inc. | $2,635 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | PRONTO | 2020 |
| 2020-01-31 | Bayer Healthcare Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | Non-Covered | Ph III Copanlisib+Rituximab in relapsed iNHL | 2020 |
| 2020-01-30 | Penumbra, Inc. | $4,623 | Research payment | Cash or cash equivalent | Artemis Device, Neurosurgery | MIND | 2020 |
| 2020-01-29 | Janssen Pharmaceuticals, Inc | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-01-25 | Merck Sharp & Dohme LLC | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | 2020 | |
| 2020-01-16 | Janssen Research & Development, LLC | $9,750 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 | |
| 2020-01-14 | Celgene Corporation | $227,151 | Research payment | Cash or cash equivalent | A SAFETY TRIAL OF LISOCABTAGENE MARALEUCEL (JCAR01 | 2020 | |
| 2020-01-06 | Janssen Research & Development, LLC | $750 | Research payment | Cash or cash equivalent | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Summit, NJ, county Union County, NJ, state New Jersey; placed by its city name.
| Measure | Place (city or town) Summit, NJ | County Union County, NJ | State New Jersey |
|---|---|---|---|
| Population B01003 | 22,705 | 579,290 | 9,343,809 |
| Population, 2020 census P1 | 22,719 | 575,345 | 9,288,994 |
| Median age B01002 | 41.8 | 39.1 | 40.1 |
| Under 18 B01001 | 24.6% | 23.5% | 21.8% |
| 65 and over B01001 | 14.6% | 15.1% | 17.2% |
| Households B11001 | 8,341 | 203,277 | 3,507,701 |
| Foreign born B05002 | 18.8% | 33.6% | 23.9% |
| Median household income B19013 | $190,304 | $103,202 | $103,556 |
| Median family income B19113 | $250,001 | $125,330 | $127,025 |
| Per capita income B19301 | $112,787 | $52,874 | $54,253 |
| Poverty rate B17001 | 5.5% | 9.2% | 9.7% |
| Unemployment rate B23025 | 5.4% | 6.5% | 6.3% |
| Civilian labor force B23025 | 12,285 | 317,599 | 5,003,179 |
| Mean commute (minutes) B08013 | 33.5 | 30.2 | 30.5 |
| Bachelor's degree or higher B15003 | 72.5% | 38.9% | 43.6% |
| Housing units B25001 | 8,786 | 212,385 | 3,791,354 |
| Owner-occupied B25003 | 68.3% | 57.4% | 63.8% |
| Renters B25003 | 31.7% | 42.6% | 36.2% |
| Median home value B25077 | $994,500 | $529,200 | $454,400 |
| Median gross rent B25064 | $2,430 | $1,730 | $1,720 |
| White, not Hispanic B03002 | 67.1% | 35.4% | 50.9% |
| Black B03002 | 5.9% | 19.1% | 12.2% |
| Hispanic or Latino B03002 | 13.1% | 35.2% | 22.5% |
| Asian B03002 | 7.3% | 5.6% | 10.0% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Summit, NJ.
Comments